Is Infinium Pharma overvalued or undervalued?

As of 24 September 2025, Infinium Pharma's valuation grade has moved from attractive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 46.46, an EV to EBITDA of 25.94, and a ROE of 14.66%. In comparison to its peers, Sun Pharma is considered expensive with a PE of 34.03, while Cipla is attractive at a PE of 22.99, highlighting how Infinium Pharma's valuation stands relative to the broader market.
Despite its fair valuation, Infinium Pharma has underperformed against the Sensex, with a year-to-date return of -15.81% compared to the Sensex's positive return of 5.97%. This underperformance, coupled with its high valuation ratios, suggests that while the company is not overvalued, it may face challenges in justifying its current price level in the near term.